Business Context and Reporting Period
This Form 8-K reports on the results of the 2017 Annual Meeting of Stockholders for Protagonist Therapeutics, Inc., held on May 25, 2017. The company is incorporated in Delaware and identifies as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Two proposals were submitted to stockholders and approved:
- Proposal 1 (Election of Directors): Two Class I directors were elected to serve until the 2020 Annual Meeting.
- Julie Papanek: 14,890,655 votes For; 224,529 votes Withheld; 191,602 Broker Non-Votes.
- Dinesh V. Patel, Ph.D.: 14,975,015 votes For; 140,169 votes Withheld; 191,602 Broker Non-Votes.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2017.
- Votes: 15,304,894 For; 1,892 Against; No Abstentions or Broker Non-Votes reported.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document serves solely to disclose the outcome of the shareholder vote.
Important Facts for Investors to Verify
- Confirmation that PricewaterhouseCoopers LLP is the appointed auditor for the fiscal year ending December 31, 2017.
- The tenure of the newly elected Class I directors (Julie Papanek and Dinesh V. Patel, Ph.D.) extending through the 2020 Annual Meeting.
- Reference to the definitive proxy statement filed on April 24, 2017, for detailed background on the proposals.